ReNewVax are pleased to announce the appointment of Dr Simon Cruwys and Dr. Carolyn Horrocks to the Board of the Company. With over 30 years experience in academic and industrial research, Simon has been involved with ReNewVax since its inception. As Head of the...
ReNewVax is proud to participate in BioInfect 2024, a major conference set to commemorate the ten-year anniversary of the influential O’Neill Review on AMR. Hosted at The Spine in Liverpool’s Knowledge Quarter, the event will bring together key figures from academia...
ReNewVax has been featured in this autumn’s edition of Drug Target Review, sharing insights into our quest for a universal pneumococcal vaccine. ‘Why innovation is the key to unlocking a universal pneumococcal vaccine’, details how the principle of reverse vaccinology...
ReNewVax has been named ‘One to Watch’ in UKTN’s 2023 guide to University Spinouts. University spinouts are companies founded to commercialise innovative technologies, products or services that have originated from academic research conducted within universities....
This month, European Pharmaceutical Review features a piece from ReNewVax’s Chief Executive Dr. Neil Murray for its Formulation issue. In the piece, Neil explores the importance of new bacterial vaccines in the context of antimicrobial resistance and examines...
